Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company developing GLSI-100 immunotherapy for breast cancer recurrence prevention, has announced updates regarding recent CEO interviews and corporate events. The company has made available several key interviews on its website, including appearances on Bloomberg TV, a fireside chat at the Noble Virtual Conference, and an interview on the Charles Schwab Network.
The company has maintained an active presence at major industry events, presenting their Flamingo-01 trial data through posters at multiple conferences including the San Antonio Breast Cancer Symposium, ESMO Breast Conference, and ASCO. GLSI has also participated in several investor conferences including the BIO CEO & Investor Conference, H.C. Wainwright BioConnect, and the Jefferies Global Healthcare Conference.
Greenwich LifeSciences (NASDAQ:GLSI), azienda biofarmaceutica in fase clinica che sviluppa l'immunoterapia GLSI-100 per prevenire le recidive del cancro al seno, ha comunicato aggiornamenti su recenti interviste del CEO e su eventi societari. Sul sito la società ha reso disponibili diverse interviste chiave, tra cui apparizioni su Bloomberg TV, un fireside chat alla Noble Virtual Conference e un'intervista alla Charles Schwab Network.
L'azienda ha mantenuto una presenza attiva nei principali eventi del settore, presentando i dati del trial Flamingo-01 tramite poster a conferenze come il San Antonio Breast Cancer Symposium, l'ESMO Breast Conference e l'ASCO. GLSI ha inoltre partecipato a diverse conferenze per investitori, tra cui la BIO CEO & Investor Conference, l'H.C. Wainwright BioConnect e la Jefferies Global Healthcare Conference.
Greenwich LifeSciences (NASDAQ:GLSI), compañía biofarmacéutica en fase clínica que desarrolla la inmunoterapia GLSI-100 para prevenir la recaída del cáncer de mama, ha anunciado actualizaciones sobre recientes entrevistas del CEO y eventos corporativos. La empresa ha puesto a disposición en su sitio web varias entrevistas clave, incluidas apariciones en Bloomberg TV, un fireside chat en la Noble Virtual Conference y una entrevista en la Charles Schwab Network.
La compañía ha mantenido una presencia activa en eventos importantes del sector, presentando los datos del ensayo Flamingo-01 mediante pósteres en conferencias como el San Antonio Breast Cancer Symposium, el ESMO Breast Conference y ASCO. GLSI también ha participado en varias conferencias para inversores, entre ellas la BIO CEO & Investor Conference, H.C. Wainwright BioConnect y la Jefferies Global Healthcare Conference.
Greenwich LifeSciences (NASDAQ:GLSI)는 유방암 재발 예방을 위한 면역치료제 GLSI-100을 개발 중인 임상 단계의 바이오제약사로, 최근 CEO 인터뷰와 기업 행사 관련 업데이트를 발표했습니다. 회사는 웹사이트에 Bloomberg TV 출연, Noble Virtual Conference의 파이어사이드 채트, Charles Schwab Network 인터뷰 등 주요 인터뷰들을 공개했습니다.
회사는 주요 업계 행사에 활발히 참여하며 Flamingo-01 임상시험 데이터를 San Antonio Breast Cancer Symposium, ESMO Breast Conference, ASCO 등 여러 학회에서 포스터로 발표했습니다. 또한 GLSI는 BIO CEO & Investor Conference, H.C. Wainwright BioConnect, Jefferies Global Healthcare Conference 등 투자자 대상 컨퍼런스에도 참여했습니다.
Greenwich LifeSciences (NASDAQ:GLSI), société biopharmaceutique en phase clinique développant l'immunothérapie GLSI-100 pour prévenir la récidive du cancer du sein, a annoncé des mises à jour concernant des interviews récentes du PDG et des événements d'entreprise. La société a mis en ligne plusieurs interviews clés sur son site, notamment des interventions sur Bloomberg TV, un fireside chat lors de la Noble Virtual Conference et une interview sur le Charles Schwab Network.
L'entreprise a maintenu une présence active lors des principaux événements du secteur, présentant les données de l'essai Flamingo-01 sous forme d'affiches lors de conférences telles que le San Antonio Breast Cancer Symposium, l'ESMO Breast Conference et l'ASCO. GLSI a également participé à plusieurs conférences investisseurs, dont la BIO CEO & Investor Conference, la H.C. Wainwright BioConnect et la Jefferies Global Healthcare Conference.
Greenwich LifeSciences (NASDAQ:GLSI), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das die Immuntherapie GLSI-100 zur Verhinderung von Brustkrebsrezidiven entwickelt, hat Aktualisierungen zu jüngsten CEO-Interviews und Unternehmensveranstaltungen bekannt gegeben. Auf der Website stellt das Unternehmen mehrere wichtige Interviews zur Verfügung, darunter Auftritte auf Bloomberg TV, einen Fireside-Chat auf der Noble Virtual Conference und ein Interview im Charles Schwab Network.
Das Unternehmen war auf bedeutenden Branchenveranstaltungen aktiv vertreten und präsentierte die Daten der Studie Flamingo-01 in Posterbeiträgen auf Konferenzen wie dem San Antonio Breast Cancer Symposium, der ESMO Breast Conference und der ASCO. GLSI nahm zudem an mehreren Investorenkonferenzen teil, darunter der BIO CEO & Investor Conference, H.C. Wainwright BioConnect und der Jefferies Global Healthcare Conference.
- None.
- None.
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events.
The following videos, which include CEO interviews, are now available on the Company’s website at the bottom of the Welcome page: https://greenwichlifesciences.com/
- Jun 28, 2025 – Interview on Bloomberg TV (recorded April 2025)
- Jun 4, 2025 – Live Fireside Chat with Research Analyst at Noble Virtual Conference
- Apr 29, 2025 – Live Interview on Charles Schwab Network with Diane King Hall
- Introductory Video
The Company's recent prior events are listed below:
- Nov 19 - 21, 2024 – Jefferies London Healthcare Conference
- Dec 10 - 13, 2024 – San Antonio Breast Cancer Symposium (SABCS) with Flamingo-01 Poster, Booth, & Conference Room
- Dec 19, 2024 – Annual Meeting of Stockholders
- Feb 10 - 11, 2025 – BIO CEO & Investor Conference
- Mar 6 - 7, 2025 – German Breast Group Annual Scientific Meeting
- May 14 - 16, 2025 – ESMO Breast Conference in Germany with Flamingo-01 Poster & Booth
- May 20, 2025 – H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
- Jun 2, 2025 – American Society of Clinical Oncology (ASCO) with Flamingo-01 Poster
- Jun 4, 2025 – Noble Emerging Growth Virtual Conference
- Jun 5, 2025 – Jefferies Global Healthcare Conference
- Jun 16 - 19, 2025 – BIO International Convention (partnering conference)
About FLAMINGO-01 and GLSI-100
FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides
For more information on FLAMINGO-01, please visit the Company's website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@greenwichlifesciences.com
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com
FAQ
What is Greenwich LifeSciences' (GLSI) main product in development?
Where has Greenwich LifeSciences presented its Flamingo-01 trial data in 2025?
What major media appearances has Greenwich LifeSciences' CEO made in 2025?
How can investors access Greenwich LifeSciences' (GLSI) recent CEO interviews?
